Moleculin Biotech Inc MBRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.39
- Day Range
- $0.38–0.42
- 52-Week Range
- $0.16–17.38
- Bid/Ask
- $0.41 / $0.41
- Shares Outstanding
- 7.10M
- Market Cap
- $2.89M
- Volume/Avg
- 1M / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 17
- Website
- https://www.moleculin.com
Valuation
|
Metric
|
MBRX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.14 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MBRX
|
|---|---|
Quick Ratio | 1.30 |
Current Ratio | 1.38 |
Interest Coverage | — |
Quick Ratio
MBRX
Profitability
|
Metric
|
MBRX
|
|---|---|
Return on Assets (Normalized) | −339.05% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
MBRX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<z?KxT | LOCK|?$g^ | $126B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|D^rT#D | LOCK|QnN$R | $81B | |||
| argenx SE ADR
ARGX
| LOCK|cl$vmz | LOCK|dQ | $55B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|bzl?JXx | LOCK|W!y?w | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Lb&Llm | LOCK|Ck | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|csQfR<t | LOCK|L@>H# | $29B | |||
| Incyte Corp
INCY
| LOCK|@?QMS< | LOCK|J^J | $24B | |||
| Moderna Inc
MRNA
| LOCK|>Y@TBG | LOCK|B! | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|>>%jhW | LOCK|ybS | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|jx^S>M | LOCK|%@? | $17B |
United States